BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
UBS
Citi
Fuji
McKinsey
Covington
US Department of Justice
Boehringer Ingelheim
Express Scripts
Queensland Health

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,288,726

« Back to Dashboard

Which drugs does patent 5,288,726 protect, and when does it expire?

Patent 5,288,726 protects EFFIENT and is included in one NDA.

Protection for EFFIENT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in twenty-five countries.
Summary for Patent: 5,288,726
Title: Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation
Abstract:Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulfonyl, haloalkanesulfonyl or sulfamoyl; R.sup.2 is optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted cycloalkylcarbonyl, substituted benzoyl, or 5,6-dihydro-1,4,2-dioxazin-3-yl; R.sup.3 is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is --NH-- or oxygen or sulfur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.
Inventor(s): Koike; Hiroyuki (Tokyo, JP), Asai; Fumitoshi (Tokyo, JP), Sugidachi; Atsuhiro (Tokyo, JP), Kimura; Tomio (Ube, JP), Inoue; Teruhiko (Ube, JP), Nishino; Shigeyoshi (Ube, JP), Tsuzaki; Yasunori (Ube, JP)
Assignee: Ube Industries Limited (Ube, JP) Sankyo Company, Limited (Tokyo, JP)
Application Number:07/941,676
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 5,288,726

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-001 Jul 10, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,288,726

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan3-227875Sep 09, 1991
Japan4-138529May 29, 1992

Non-Orange Book US Patents Family Members for Patent 5,288,726

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,436,242 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,288,726

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 169627 ➤ Subscribe
Australia 2284792 ➤ Subscribe
Australia 656798 ➤ Subscribe
Canada 2077695 ➤ Subscribe
China 1041730 ➤ Subscribe
China 1074446 ➤ Subscribe
China 1107502 ➤ Subscribe
China 1217186 ➤ Subscribe
Czech Republic 287181 ➤ Subscribe
Czech Republic 9202784 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Cipla
Accenture
Cerilliant
Baxter
Citi
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot